Abnormal methylation characteristics predict chemoresistance and poor prognosis in advanced high-grade serous ovarian cancer

Table 5 The relationship between CpGs methylation and PFS in advanced HGSOC

CpGid	Advanced HGSOC (the total group)			Advanced HGSOC with complete debulking			Advanced HGSOC with incomplete debulking
CpGid	Mean (months)	95% CI	P	Mean (months)	95% CI	P	Mean (months)	95% CI	P
cg21105318
Hypomethylation	22.98	19.43–26.52	0.020	25.63	22.65–28.60	0.086	20.33	12.63–28.04	0.08
Hypermethylation	16.18	13.13–19.23		18.07	14.00–22.14		12.39	9.00–15.78
cg07896068
Hypomethylation	20.55	17.44–23.66	0.006	23.50	19.92–27.09	0.004	16.14	11.04–21.25	0.343
Hypermethylation	13.66	9.74–17.57		14.14	8.43–19.86		12.30	8.04–16.56
cg27637873
Hypomethylation	21.36	18.02–24.70	0.010	23.89	20.20–27.58	0.015	16.67	10.43–22.91	0.437
Hypermethylation	15.18	11.59–18.78		16.27	11.00–21.53		13.00	9.10–16.90
cg26782361
Hypomethylation	20.66	17.33–23.99	0.019	22.86	18.89–26.83	0.068	17.17	11.55–22.79	0.168
Hypermethylation	15.08	11.35–18.81		17.18	11.84–22.51		11.25	8.04–14.46
cg16265707
Hypomethylation	20.37	17.21–23.52	0.013	22.89	19.27–26.52	0.022	16.23	10.76–21.71	0.309
Hypermethylation	14.37	10.41–18.33		16.14	10.22–22.06		12.55	8.56–16.53
cg20937934
Hypomethylation	21.97	18.07–25.87	0.023	24.30	20.15–28.45	0.073	18.00	10.04–25.96	0.212
Hypermethylation	15.63	12.35–18.91		16.80	12.19–21.42		12.88	9.44–16.33

ISSN: 1868-7083